Skip to main content

Advertisement

Log in

Outcome of Treatment for Medullary Thyroid Carcinoma—a Single Centre Experience

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

We conducted this study to evaluate the demography, clinical presentation, management and outcomes of medullary thyroid carcinoma (MTC) from the Indian context. This was a retrospective study of patients with MTC managed between January 2008 and December 2016. All pertinent data was collected and the results were analysed using STATA (v.13.1). MTC accounted for 90/2022 (4.45%) patients managed with thyroid cancer during the study period. The mean age of presentation was 40 years (range 14–70 years) with 47 males and 43 females. The most common presentation included goitre with cervical lymphadenopathy seen in 60 patients (66.7%). There were 11 patients (12.2%) with systemic metastasis at presentation. Rearranged during transfection (RET) testing was performed in 71 patients and was positive in 25 (35.2%). The mutations among these patients were seen in the following codons: 634 (12), 804 (8), 790 (3) and 618 (2). Persistent hypercalcitoninemia (calcitonin > 50 pg/ml) was observed in 62/80 (77.5%) patients. Forty patients underwent a meta-iodo-benzyl-guanidine (MIBG) scan in the postoperative period, 10 were positive. The mean duration of follow-up was 32 months and 10 patients defaulted from follow-up. Sixteen patients developed metastasis during the period of follow-up while eight patients expired. The mean survival was 85.75 months (95% CI 78.7–92.7). MTC accounted for 4.5% of thyroid carcinomas in this cohort among which 35% were hereditary. Persistent hypercalcitoninemia following surgery is seen in more than 70% of patients but this does not affect survival. RET screening should be performed for all patients with MTC as curative surgery can be offered for mutation positive offspring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc 25(6):567–610. https://doi.org/10.1089/thy.2014.0335

    Article  Google Scholar 

  2. Allen SM, Bodenner D, Suen JY, Richter GT (2009) Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma. Laryngoscope 119(7):1303–1311. https://doi.org/10.1002/lary.20299

    Article  PubMed  Google Scholar 

  3. Rowland KJ, Moley JF (2015) Hereditary thyroid cancer syndromes and genetic testing. J Surg Oncol 111(1):51–60. https://doi.org/10.1002/jso.23769

    Article  PubMed  Google Scholar 

  4. Pai R, Nehru GA, Samuel P, Paul MJ, Thomas N, Premkumar JA, Hephzibah J, Shanthly N, Oommen R, Nair A, Seshadri MS, Rajaratnam S (2011) Mutational analysis of RET proto-oncogene among patients with medullary thyroid carcinoma and ‘at risk’ carriers from India. Clin Endocrinol 75(4):571–572. https://doi.org/10.1111/j.1365-2265.2011.04069.x

    Article  Google Scholar 

  5. Nosé V (2011) Familial thyroid cancer: a review. Mod Pathol 24:S19–S33. https://doi.org/10.1038/modpathol.2010.147

    Article  PubMed  Google Scholar 

  6. Calvo J, Torrealba G, Sáenz A, Santamaría C, Morera E, Alvarado S, et al. Genetic and clinical features of medullary thyroid carcinoma: the experience of a single center in Costa Rica. J Cancer Epidemiol [Internet]. 2016 [cited 2017 Jan 5]; 2016. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149694/

  7. Randolph GW, Maniar D (2000) Medullary carcinoma of the thyroid. Cancer Control 7(3):253–253. https://doi.org/10.1177/107327480000700305

    Article  CAS  PubMed  Google Scholar 

  8. Sakorafas GH, Friess H, Peros G (2008) The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr Relat Cancer 15(4):871–884. https://doi.org/10.1677/ERC-08-0098

    Article  CAS  PubMed  Google Scholar 

  9. Correia-Deur JEM, Toledo RA, Imazawa AT, Lourenco DM Jr, Ezabella MC et al (2009) Sporadic medullary thyroid carcinoma: clinical data from a university hospital. Clinics 64(5):379–386

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H (2004) Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg 28(12):1271–1274. https://doi.org/10.1007/s00268-004-7608-9

    Article  PubMed  Google Scholar 

  11. Simões-Pereira J, Bugalho MJ, Limbert E, Leite V (2016) Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution. Oncol Lett 11(6):3870–3874. https://doi.org/10.3892/ol.2016.4482

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lee CR, Lee S, Son H, Ban E, Kang S-W, Lee J, Jeong JJ, Nam KH, Chung WY, Park CS (2016) Medullary thyroid carcinoma: a 30-year experience at one institution in Korea. Ann Surg Treat Res 91(6):278–287. https://doi.org/10.4174/astr.2016.91.6.278

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q, Eisenberger CF, Röher HD, Knoefel WT (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246(5):815–821. https://doi.org/10.1097/SLA.0b013e31813e66b9

    Article  PubMed  Google Scholar 

  14. Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma. Ann Surg 229(6):880. https://doi.org/10.1097/00000658-199906000-00016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130(6):1044–1049. https://doi.org/10.1067/msy.2001.118380a

    Article  CAS  PubMed  Google Scholar 

  16. Moley JF (2010) Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Cancer Netw 8(5):549–556. https://doi.org/10.6004/jnccn.2010.0042

    Article  Google Scholar 

  17. Bugalho MJM, Santos JR, Sobrinho L (2005) Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 91(1):56–60. https://doi.org/10.1002/jso.20269

    Article  PubMed  Google Scholar 

  18. de Crea C, Raffaelli M, Maccora D, Carrozza C, Canu G, Fadda G, Bellantone R, Lombardi CP (2014) Calcitonin measurement in fine-needle aspirate washouts vs. cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma. Acta Otorhinolaryngol Ital 34(6):399–405

    PubMed  Google Scholar 

  19. Lorente-Poch L, Sancho JJ, Muñoz-Nova JL, Sánchez-Velázquez P, Sitges-Serra A (2015) Defining the syndromes of parathyroid failure after total thyroidectomy. Gland Surg 4(1):82–90. https://doi.org/10.3978/j.issn.2227-684X.2014.12.04

    PubMed  PubMed Central  Google Scholar 

  20. Brennan PA, Blythe JN, Herd MK, Habib A, Anand R (2012) The contemporary management of chyle leak following cervical thoracic duct damage. Br J Oral Maxillofac Surg 50(3):197–201. https://doi.org/10.1016/j.bjoms.2011.02.001

    Article  CAS  PubMed  Google Scholar 

  21. Dralle H, Gimm O, Simon D, Frank-Raue K, Görtz G, Niederle B et al (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22(7):744–751

  22. Schreinemakers JMJ, Vriens MR, Valk GD, de Groot J-WB, Plukker JT, Bax KMA et al (2010) Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J Surg 34(4):852–860

  23. Sousa A de A, Salles JMP, Soares JMA, Moraes GM de, Carvalho JR, Savassi-Rocha PR (2012) Predictors factors for post-thyroidectomy hypocalcaemia. Rev Col Bras Cir 39(6):476–482

  24. Kluijfhout WP, van Beek D-J, Verrijn Stuart AA, Lodewijk L, Valk GD, van der Zee DC et al (2015) Postoperative complications after prophylactic thyroidectomy for very young patients with multiple endocrine neoplasia type 2. Medicine (Baltimore) 94(29):e1108

  25. Machens A, Dralle H (2012) Simultaneous medullary and papillary thyroid cancer: a novel entity? Ann Surg Oncol 19(1):37–44

  26. Biscolla RP, Ugolini C, Sculli M, Bottici V, Castagna MG, Romei C et al (2004) Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 14(11):946–952

  27. Kim WG, Gong G, Kim EY, Kim TY, Hong SJ, Kim WB et al (2010) Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental. Clin Endocrinol (Oxf) 72(2):256–263

  28. Finny P, Jacob JJ, Thomas N, Philip J, Rajarathnam S, Oommen R et al (2007) Medullary thyroid carcinoma: a 20-year experience from a centre in south India. ANZ J Surg 77(3):130–134

  29. Van Veelen W, Groot D, B JW, Acton DS, Hofstra RMW, Höppener JWM et al (2009) Medullary thyroid carcinoma and biomarkers: past, present and future. J Intern Med 266(1):126–140

  30. Fialkowski E, DeBenedetti M, Moley J (2008) Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32(5):754–765

  31. Kebebew E, Kikuchi S, Duh QY, Clark OH (2000) Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135(8):895–901

  32. Tisell LE, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99(1):60–66

  33. Castellani MR, Seregni E, Maccauro M, Chiesa C, Aliberti G, Orunesu E et al (2008) MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging 52(4):430–440

  34. Ilias I, Divgi C, Pacak K (2011) Current role of MIBG in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med 41(5):364–368

  35. Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L (2000) Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25(2):273–282

  36. Terezakis SA, Lee NY (2010) The role of radiation therapy in the treatment of medullary thyroid cancer. J Natl Compr Cancer Netw 8(5):532–540

  37. Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD (2010) Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 102(2):175–178

  38. Brierley JD (2011) Update on external beam radiation therapy in thyroid cancer. J Clin Endocrinol Metab 96(8):2289–2295

  39. Sippel RS, Kunnimalaiyaan M, Chen H (2008) Current management of medullary thyroid cancer. The Oncologist 13(5):539–547

  40. Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6):475–485

  41. A T, F S, G P, M B (2011) Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics 12(8):618–625

  42. Jiménez C, Hu MI-N, Gagel RF (2008) Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 37(2):481–496

  43. Machens A, Dralle H (2008) Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf) 69(1):81–87

  44. Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Uberta V, Boscaro M, Castagna MG, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R (2010) Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 163(6):963–963

  45. Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R (2015) Twenty years of lesson learning: how does the genetic screening test impact the clinical management of medullary thyroid cancer? Clin Endocrinol 82(6):892–899

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anish Jacob Cherian.

Ethics declarations

Conflict of Interest

All authors declare that they have no conflict of interest.

Human Rights and Inform Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cherian, A.J., Ramakant, P., Pai, R. et al. Outcome of Treatment for Medullary Thyroid Carcinoma—a Single Centre Experience. Indian J Surg Oncol 9, 52–58 (2018). https://doi.org/10.1007/s13193-017-0718-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-017-0718-2

Keywords

Navigation